On Friday, we welcomed Professor Shigeo Ohta to the Czech Republic — a world-renowned authority in the field of molecular hydrogen and co-founder of H2 Global Group.
Together with Czech experts, we are officially launching the first clinical study in the Czech Republic focused on the use of molecular hydrogen in patients with mild cognitive impairment (MCI).
🔹 January 19, 2026 – study launch
🔹 January 22, 2026 at 2:00 PM – press conference at ČTK Prague (media and partners welcome)
As Prof. Ohta stated:
“…together with the team in the Czech Republic, we want to change the field so that it has a standardized pathway toward regulatory registration.”
Our goal is clear: to clinically validate, standardize, and advance the technology into the EU regulatory framework, and subsequently open space for international cooperation, clinical partners, and strategic investors.
Full article here: Vědecká autorita z Japonska, profesor Shigeo Ohta, přicestoval do Česka: skupina H2 Global Group spouští v ČR klinickou studii s molekulárním vodíkem – Metro.cz